Last week we saw some major excitement on the colon cancer treatment front. According to a recent press release, the FDA approved Lonsurf, a pill intended to treat advanced colon cancer in patients who are no longer responding to other treatments.
The approval came after the FDA evaluated an 800-person trial that tested the safety and efficacy of Lonsurf. The study showed that patients who took the drug lived an average of two months longer than those treated with a placebo.
“The past decade has brought a new understanding around colorectal cancer, in how we can both detect and treat this often devastating disease,” said Richard Pazdur, M.D., in the press release. Dr. Pazdur is the director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.
“But there are many patients who still need additional options, and today’s approval is a testament to the FDA’s commitment to work with companies to develop new drugs in disease areas where unmet needs remain.”
Lonsurf is recommended for patients with advanced (metastatic) colon cancer who have previously received chemotherapy and biological therapy treatments to no avail. The drug is an oral medication manufactured by Taiho Oncology Inc. in Princeton, New Jersey.
Other News From Around the Web
- Here's a recent study in which researchers evaluated the differences between tumors in younger and older colon cancer patients.
- Can dried plums aid in the prevention of colon cancer? This study from Texas A&M and the University of North Carolina suggests they can.
- New research shows that patients with inflammatory bowel disease (IBD) may only need to undergo a colonoscopy every five years.
- The state of Michigan has received a grant from the Centers for Disease Control and Prevention (CDC) to increase colon cancer screening rates by 2018.
Image Source: Pexels.com